Literature DB >> 16283191

[Lavasept as an alternative to PVP-iodine as a preoperative antiseptic in ophthalmic surgery. Randomized, controlled, prospective double-blind trial].

F Hansmann1, A Kramer, H Ohgke, H Strobel, M Müller, G Geerling.   

Abstract

BACKGROUND: To reduce the risk of endophthalmitis PVP-iodine is typically used preoperatively. Since iodine is contraindicated in patients with a specific allergic history or severe thyroid disorder we studied the effect of Lavasept, which contains Polyhexanid as an antiseptic alternative. PATIENTS AND METHODS: In a randomized controlled double-blind trial 3 drops of 0.2% Lavasept, 1.25% PVP-iodine or Ringer's solution were applied preoperatively to 67 patients, which have had a minimum of 5 colony forming units (cfu's) in the conjunctival swap. The effectiveness and tolerability were measured.
RESULTS: After application of Lavasept or PVP-iodine, the number of cfu was statistically significantly reduced. Lavasept reduced the number of bacterial colonies significantly better than PVP-iodine (p=0.05). All test solutions were equally well tolerated.
CONCLUSION: The use af Lavasept is safe, well tolerated and reduces the microbiological contamination of the conjunctival fornix effectively. lt provides a more effective reduction of the cfu's than PVP-iodine 1.25% and this effect tends to be prolonged. Lavasept is a good alternative option in ophthalmology for preoperative antisepsis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283191     DOI: 10.1007/s00347-004-1120-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  16 in total

1.  [Effectiveness of an improved antiseptic in treatment of contaminated soft tissue wounds].

Authors:  K P Schmit-Neuerburg; C Bettag; W Schlickewei; W Fabry; J Hanke; K Renzing-Köhler; H Hirche; H J Kock
Journal:  Chirurg       Date:  2001-01       Impact factor: 0.955

2.  Antimicrobial efficacy of antiseptic mouthrinse solutions.

Authors:  F A Pitten; A Kramer
Journal:  Eur J Clin Pharmacol       Date:  1999-04       Impact factor: 2.953

Review 3.  Efficacy and tolerance of selected antiseptic substances in respect of suitability for use on the eye.

Authors:  A Kramer; P Rudolph
Journal:  Dev Ophthalmol       Date:  2002

4.  [Preventive intraoperative irrigation in wound management with Lavasept. Report of experiences with 1,610 cases].

Authors:  B Roth; K Baltzer
Journal:  Z Unfallchir Versicherungsmed       Date:  1990

5.  Combined treatment of Acanthamoeba keratitis with propamidine, neomycin, and polyhexamethylene biguanide.

Authors:  J H Varga; T C Wolf; H G Jensen; V C Parmley; J J Rowsey
Journal:  Am J Ophthalmol       Date:  1993-04-15       Impact factor: 5.258

6.  Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide.

Authors:  D F Larkin; S Kilvington; J K Dart
Journal:  Ophthalmology       Date:  1992-02       Impact factor: 12.079

7.  Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes.

Authors:  T M Aaberg; H W Flynn; J Schiffman; J Newton
Journal:  Ophthalmology       Date:  1998-06       Impact factor: 12.079

8.  [Bacteriocidal effect of preoperative use of gentamicin in comparison with PVP-iodine solution].

Authors:  C R Maeck; C Eckardt; C Höller
Journal:  Fortschr Ophthalmol       Date:  1991

9.  Bacterial flora in relation to cataract extraction. V. Effects of topical antibiotics on the preoperative conjunctival flora.

Authors:  J A Fahmy
Journal:  Acta Ophthalmol (Copenh)       Date:  1980-08

10.  A standardized test to assess the impact of different organic challenges on the antimicrobial activity of antiseptics.

Authors:  F-A Pitten; H-P Werner; A Kramer
Journal:  J Hosp Infect       Date:  2003-10       Impact factor: 3.926

View more
  1 in total

Review 1.  ["Iodine allergy" : A medical myth with risks for the ophthalmological patient].

Authors:  T U Krohne; J-P Allam; N Novak; F G Holz
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.